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w/o, 28% with TLR5-stop) and a signiﬁcant increase of 1yr TRM
(25% to 39%, p 0.01) as well as overall TRM, which translated
in decreased overall survival (51% vs 33%, p 0.002). The effect
was strongest in the subgroup of younger and early stage pts
receiving HLA-identical sibling SCT; in addition, combined
analysis of TLR5-stop and NOD2/CARD15 SNPs suggested a
potential synergism, as 1 yr TRM was 21% in the absence of
both SNPs, 32 and 33% in the presence of either TLR5-stop or
NOD2/CARD15 and 66% in the presence of both. In multivar-
iate cox regression analysis of risk factors for 1yr TRM, older
recipient age (HR1.5, p 0.04), female donor in a male recipient
(HR 1.7, p 0.01) and presence of TLR5-stop (HR 1.6, p 0.05) and
NOD2/CARD15 SNPs (HR 1.8, p 0.004) in the recipient were
conﬁrmed as independent risk factors.
As both, TLR- stop and NOD2/CARD15 SNPs have been associ-
ated with functional defects, our observations further support the
concept of a major role of altered innate immune responses in the
pathophysiology of GvHD associated complications following al-
logeneic SCT.
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IMMATURE DENDRITIC CELLS DOWNREGULATE GRAFT VERSUS HOST
REACTIONS IN THE HUMAN SKIN EXPLANT MODEL AFTER CO-CUL-
TURE WITH IN VITRO PUVA TREATED LYMPHOCYTES
Holtick, U.1, Marshall, S.P.1, Hilkens, C.M.U.2, Wang, X.N.1,
Dickinson, A.M.1 1Haematological Sciences; 2Immunotherapy Group,
Medical School, Newcastle University, Newcastle upon Tyne, United
Kingdom.
Extracorporeal Photopheresis (ECP) can be successfully used
to treat steroid refractory Graft versus Host Disease (GvHD)
after allogeneic hematopoietic stem cell transplantation. ECP is
well tolerated and, different from conventional immunosuppres-
sants, does not increase infection or relapse rates. One suggested
scenario is that dendritic cells (iDC) might be modulated by
ECP treated apoptotic lymphocytes and aquire a tolerogenic
phenotype to downregulate inﬂammation in GvHD. We at-
tempted to test this hypothesis using the human skin explant
model.
Responder PBMCs and monocytes were derived from healthy
donor buffy coats. Skin and stimulator cells were derived from
patients after informed consent and ethical approval. A mixed
lymphocyte reaction was set up. On day 4 responder cells were
taken from the MLR. Apoptotic and dead cells were removed
before treating half of the cells with in vitro PUVA (Psoralen,
UVA) simulating ECP treatment. After 20h, the untreated or in
vitro PUVA treated cells were added to monocyte derived im-
mature DCs of responder origin and co-cultured overnight. The
respective dendritic cells then were isolated via FACS sorting
and added back to the ongoing MLR at a ratio of 1:10 (DC :
MLR responder). Immature DCs were added at the same ratio
to a third ﬂask. Medium and Responder cells served as negative
and positive control. After 48h 1106 responder cells from the
respective setup were given to skin sections derived from a
dermabrasio. After 3 days the skin was routinally ﬁxed and
stained before evaluating the GvH grade using the Lerner scale.
Results: Immature DCs which had been in co-culture with in
vitro PUVA treated PBMCs, but none of the controls, down-
regulated GvH reactions in the skin explant model from Grade
III to grade I. MLR supernatants tested so far show reduced
IFN- and TNF-
 levels but no difference in IL-10 and IL-4
production. We are currently extending cytokine analysis and
are further characterizing the apoptotic cells’ inﬂuence on DCs
in our model. FACS analysis of immature DCs after co-culture
with apoptotic cells revealed upregulation of PDL-1 as a pos-
sible mechanism for lymphocyte suppression. Further investi-
gation should reveal whether origin of the apoptotic cells or the
method apoptosis is induced by are relevant for the observed
effects.
Using the human skin explant model we could show that mod-
ulation of immature DCs by ECP/in vitro PUVA treated lympho-
cytes downregulates GvH reactions.
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SELECTIVE EXPANSION OF HUMAN REGULATORY (CD4CD25
CD127LOWFOXP3) CELLS TO HIGH PURITY BY INHIBITING EXPAN-
SION OF CD4CD25CD127HIGHFOXP3- CONVENTIONAL T CELLS
WITH RAPAMYCIN
Hou, J.-Z.1,2, Zambricki, E.1, Zeiser, R.1, Negrin, R.S.1 1Division of
Bone Marrow Transplantation, School of Medicine, Stanford University,
Stanford, CA; 2Division of Hematology, School of Medicine, Stanford
University, Stanford, CA.
CD4CD25FOXP3 natural occurring T regulatory (Treg) cells
possess great therapeutic potential as adoptive cellular therapy for
controlling acute GVHD. However, their clinical application is lim-
ited by the difﬁculty of obtaining sufﬁcient numbers of
CD4CD25FOXP3 cells. This study explored a strategy to ex-
pand human Treg in high purity and high numbers. By comparing
expression of cell surface molecules on sorted CD4CD25high vs.
CD4CD25- cells using mAb microarray, we identiﬁed CD127 was
highly expressed in CD4CD25- and CD4CD25Low cells in human
PBMC. Incorporating this new discovery, CD4CD25 cells were
isolated by CD25 selection from PBMC, sorted into
CD4CD25HighCD127Low and CD4CD25lowCD127High cells.
FOXP3 were positive in 94% of CD4CD25HighCD127Low cells,
and 5% in CD4CD25lowCD127High cells. The sorted cells were
expanded with and without rapamycin in X-vivo medium containing
IL-2 and anti-CD3/CD28 beads for a total of 21 days. In the absence
of rapamycin, CD4CD25HighCD127Low cells expanded expanded
156 and 1560 folds, yet only 30% and 20% of expanded cells were
positive for FOXP3 at day 14 and 21 respectively. In the presence of
rapamycin CD4CD25HighCD127Low cells remain FOXP3 in
96%, 60% and 56% at days 7, 14 and 21. However, the number of
cells increased only 19, 36, and 21 folds at days 7, 14 and 21 respec-
tively. To overcome the insufﬁcient expansion of
CD4CD25HighCD127Low cells in the presence of rapamycin, anti-
CD3mAb (OKT3) or anti-CD3/CD28 beads was added to the media
at day 7 after the initial beads were removed and cultured until day 21.
At day 14, 66% of the cells were FOXP3 positive with rapamycin and
anti-CD3 and 80% for cells with rapamycin and ani-CD3/CD28
beads. The numbers of cells were expanded: 13 folds with rapamycin
and anti-CD3, and 238 folds with rapamycin and ani-CD3/CD28
beads. At day 21, the numbers of cells were expanded: 34 folds with
rapamycin and anti-CD3, and 2856 folds with rapamycin and ani-
CD3/CD28 beads. In contrast, CD4CD25lowCD127High cells ex-
panded in the same condition as controls had much lower percentages
of FOXP3 cells. In summary, in the presence of rapamycin,
CD4CD25HighCD127LowFOXP3 cells were preferentially ex-
panded with IL-2 and anti-CD3/CD28 beads. Continued stimulation
from anti-CD3/CD28 beads enhanced the expansion of
CD4CD25HighCD127LowFOXP3 cells. The suppressive function
was positively correlated with the percentage of FOXP3 cells in the
MLR culture.
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TREATMENT OF SEVERE OCULAR SURFACE DISEASE FROM OCULAR
CHRONIC GRAFT-VERSUS-HOST DISEASE WITH A SCLERAL LEN PROS-
THETIC DEVICE
Jacobs, D.S.1,2, Rosenthal, P.1,2 1Boston Foundation for Sight, Needham,
MA; 2Harvard Medical School, Boston, MA.
Purpose: The ﬂuid-ventilated, gas-permeable scleral lens pros-
thetic device is an innovative treatment for ocular surface disease.
Retrospective studies of patients with severe dry eye ﬁtted with
these lenses report mitigation of symptoms, improvement in func-
tion and quality of life, and healing of persistent epithelial defects
of the corneal surface. This prospective study is designed to mea-
sure the impact of this device on visual function in patients with
ocular chronic graft-versus-host disease (cGvHD) unresponsive to
conventional therapy.
Methods: All patients referred to this institution for scleral lens
consultation from January through June 2006 were administered
the VFQ-25 at entry, and again 6 months later. The National Eye
Institute sponsored the development of the VFQ-25 as a standard-
ized, validated survey instrument to measure the dimensions of
self-reported vision-targeted health status in persons who have
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